These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 26502667)
1. [Draft guideline regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors Drafting Committee for Guideline of Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine]. Kinuya S; Yoshinaga K; Higuchi T; Jinguji M; Kawamoto H; Kurihara H Kaku Igaku; 2015 Feb; 52(1):1-15. PubMed ID: 26502667 [TBL] [Abstract][Full Text] [Related]
2. Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors : Guideline Drafting Committee for Radiotherapy with (131)I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine. Kinuya S; Yoshinaga K; Higuchi T; Jinguji M; Kurihara H; Kawamoto H; Ann Nucl Med; 2015 Jul; 29(6):543-52. PubMed ID: 25773397 [TBL] [Abstract][Full Text] [Related]
3. [Guideline draft of appropriate use of 131I-MIBG for internal radiotherapy of neuroendocrine tumors]. Nakajo M; Yoshinaga K; Oriuchi N; Kinuya S; Yokoyama K; Yamaguchi T; ; ; Kaku Igaku; 2008 Feb; 45(1):suppl 1-40. PubMed ID: 19594094 [TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Buscombe JR; Cwikla JB; Caplin ME; Hilson AJ Nucl Med Commun; 2005 Nov; 26(11):969-76. PubMed ID: 16208174 [TBL] [Abstract][Full Text] [Related]
5. 131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis. Rahimi B; Makis W; Riauka TA; McEwan AJ; Morrish D Clin Nucl Med; 2017 May; 42(5):350-353. PubMed ID: 28240668 [TBL] [Abstract][Full Text] [Related]
6. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Castellani MR; Chiti A; Seregni E; Bombardieri E Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604 [TBL] [Abstract][Full Text] [Related]
7. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ; Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026 [TBL] [Abstract][Full Text] [Related]
8. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501 [TBL] [Abstract][Full Text] [Related]